Korean J Schizophr Res.  2016 Oct;19(2):60-67. 10.16946/kjsr.2016.19.2.60.

Prevalence of Sexual Dysfunction in Schizophrenic Patients Taking Antipsychotic Drugs

• Jeong SH
• Kang SH
• Park DY
• Yoon HJ
• Park EK
• Lee JI

• KMID: 2357028
• DOI: http://doi.org/10.16946/kjsr.2016.19.2.60

Abstract

OBJECTIVES
Sexual dysfunction is said to affect the compliance of drug and quality of life. This study is a research to investigate the prevalence of sexual dysfunction and affecting factors that can occur when schizophrenic and schizoaffective patients have taken drugs.
METHODS
Subjects were 300 patients who have been taken inpatient or outpatient treatment in national seoul hospital. We used UKU-S, ASEX scale for evaluating the prevalence of sexual dysfunction and CGI-S, PANSS negative scale and CES-D for investigating the influence of psychopathology and depressive symptoms on sexual dysfunction.
RESULTS
It was reported sexual dysfunction 82.7% in male and 92.2% in female with 7 items of UKU-S. The prevalence of sexual dysfunction with criteria of ASEX was 47.72% in male and 65.05% in female. Sexual dysfunction was more prevalent in patients taking prolactin-elevation drugs. In the factor analysis for the sexual dysfunction it was investigated that age, onset time, CGI-S, PANSS negative scale, and CES-D can affect the sexual dysfunction in both male and female.
CONCLUSION
This study reported that many patients complained of sexual dysfunction. On considering the influence of sexual dysfunction to compliance and quality of life, clinicians evaluate sexual side effects more actively because patients are more likely not spontaneously tell the sexual side effects in comparison to others.

Keyword

Sexual dysfunction; Schizophrenia; Antipsychotic agent

MeSH Terms

Antipsychotic Agents*
Compliance
Depression
Female
Humans
Inpatients
Male
Outpatients
Prevalence*
Psychopathology
Quality of Life
Schizophrenia
Seoul
Antipsychotic Agents

Reference

References

1. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. Journal of Sexual Medicine. 2016; 13:153–167.

2. Fric M, Laux G. Prolactin levels and symptoms of hyperprolactinaemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine. Psychiatr Prax. 2003; 30:97–101.

3. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002; 181:49–55.

4. Richard GP. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999; 35:67–73.

5. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2001; 36:143–164.

6. Yasui-Furukori N, Fujii A, Sugawara N, Tsuchimine S, Saito M, Hashimoto K, et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol. 2012; 27:82–89.

7. Dossenbach M, Hodge A, Anders M, Molnár B, Peciukaitiene D, Krupka-Matuszczyk I, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol. 2005; 8:195–201.

8. Uçok A, Incesu C, Aker T, Erkoç S. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry. 2007; 22:328–333.

9. Fujii A, Yasui-Furukori N, Sugawara N, Sato Y, Nakagami T, Saito M, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34:288–293.

10. Choi YT, Cheon JS, Oh BH. Review of sexual dysfunction in male schizophrenics. J Korean Soc Biol Psychiatry. 2000; 7:85–98.

11. Lee KH, Kang SH, Kang GY, Kim KH, Kim KK, Soh M, et al. The prevalence of hyperprolactinemia and amenorrhea and the association with sexual dysfunction in schizophrenic patients with antipsychotics. J Korean Neuropsychiatr Assoc. 2009; 48:423–429.

12. Olfson M, Uttaro T, Carson WH. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005; 66:331–338.

13. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006; 124:291–297.

14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association;2000.

15. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007; 27:639–661.

16. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007; 68:213–223.

17. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry. 2002; 63:992–997.

18. Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008; 22:56–62.

19. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and longterm effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997; 26:41–54.

20. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 1899; 64:663–667.

21. Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW, McGrath PJ, Ross D, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol. 1986; 6:144–149.

22. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001; 62:10–21.

23. Guy W. Clinical Global Impressions (CGI) Scale. Modified From: Rush J, et al.: Psychiatric Measures, APA, Washington DC;2000.

24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261–276.

25. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement. 1977; 1:385–401.

26. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000; 26:25–40.

27. Martha S, Luis FR. Rating scales in mental health. Revised. 2nd ed.Lexi-comp;2006. p. 376–378.

28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987; 76:1–100.

29. Schwartz MF, Bauman JE, Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psychiatry. 1982; 17:861–876.

30. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002; 20:365–374.

31. Westheide J, Cohen S, Bender S, Cooper-Mahkorn D, Erfurth A, Gastpar M, et al. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry. 2007; 40:140–145.

32. Harley EW, Boardman J, Craig T. Sexual problems in schizophrenia: prevalence and characteristics. A cross sectional survey. Soc Psychiatry Psychiatr Epidemiol. 2010; 45:759–766.

33. Rettenbacher MA, Hofer A, Ebenbichler C, Baumgartner S, Edlinger M, Engl J, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010; 30:711–715.

34. Smith S, Gillam A. Sexual dysfunction-the forgotten taboo. Mental Health Nurs. 2005; 25:6–9.

35. Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebocontrolled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006; 163:494–499.

36. Seeman MV. Loss of libido in a woman with schizophrenia. Am J Psychiatry. 2013; 170:471–475.

37. Hou CL, Zang Y, Rosen RC, Cai MY, Li Y, Jia FJ, et al. Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care. Comprehensive Psychiatry. 2016; 65:116–121.